The radiation sensitivity of primary clonogenic blasts from 44 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (ALL) was analyzed using leukemic progenitor cell (LPC) colony assays. The derived values for SF2 (surviving fraction at 200 cGy) and a (initial slope of radiation survival curves constructed according to the linear quadratic model) indicated a marked interpatient heterogeneity in intrinsic radiation sensitivity of LPC populations. The SF2 values ranged from 0.01 to 1.00 (median = 0.430; mean±SE = 0.47±0.04), and the a values ranged from 0.000 to 3.272
Introduction
High risk acute lymphoblastic leukemia (ALL)' patients typically suffer a poor outcome after conventional drug treatment protocols (1) . Within the last decade, however, total body irradiation (TBI) and high dose chemotherapy have been applied before bone marrow transplantation (BMT) in aggressive regimens to enhance these patients' prospects for disease-free survival (2) (3) (4) (5) (6) (7) (8) (9) . Although improvements in long-term, disease-free survival have been reported, recurrence ofleukemia within the first 6 mo after TBI and BMT continues to be a major obstacle to a more successful outcome after BMT for high risk ALL, and only < 20% of high risk ALL patients become long-term, disease-free survivors after autologous or allogeneic BMT (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The Until we learn more about the effects of TBI on LPC, the results of radiation based pre-BMT conditioning regimens are not likely to dramatically improve. A thorough radiobiologic analysis of primary clonogenic blasts from ALL patients is a requisite step toward greater understanding of clinical radiation resistance. The present study initiated this task by evaluating the radiation sensitivity of primary clonogenic blasts from 44 newly diagnosed B-cell precursor ALL patients. Two computer-based models of cell survival were used (14) . The multitarget model of survival curve analysis (14) (15) (16) provides SF2 values as parameters to describe intrinsic radiation sensitivity. The surviving fraction at 200 cGy (SF2) value is the surviving fraction of clonogenic blasts after exposure to 200 cGy. The major parameter for intrinsic radiation sensitivity in the linear quadratic model (14) (15) (16) is the a value, representing the initial slope ofthe linear component ofthe continuously bending radiation dose survival curve. Clonogenic blasts are considered sensitive to radiation based on high a values and low SF2 values.
We initially recorded a marked interpatient variation in the values obtained from survival curves generated by LPC. Clonogenic blasts from different B-cell precursor ALL 4 to 23% (median = 13%; mean±SE = 12±1%) and the proliferation index (PI = % S+ %G2M) ranged from 5 to 28% (median = 15%; mean±SE = 15± 1%).
The immunophenotypic features of leukemic blasts were determined by immunofluorescence staining and flow cytometry using a broad panel of mAb reactive with lymphoid differentiation antigens. None of 44 patients expressed the pan-T cell antigens CD2, CD5, and CD7 or the mature B-cell marker surface immunoglobulin. In contrast, leukemic blasts from each of the 44 patients expressed high levels of CD19 and/or CD24 B-lineage differentiation antigens. 89±1% of leukemic blasts from 44 of 44 (100%) expressed CD 19, 83±3% of leukemic blasts from 34 of40 patients (85%) expressed CD24, and 57±4% of leukemic blasts from 10 of 28 patients (36%) expressed CD40 antigen. The lymphoid precursor cell antigen CD1O was expressed on 82±3% of leukemic blasts from 33 of44 (75%) patients. The progenitor cell associated antigen CD34 was expressed on 76±5% of leukemic blasts from 17 of 31 patients (55%). Thus, leukemic blasts displayed a common composite immunophenotype (CD2-CD5 -CD7 -CD10'/-CD19+ CD24+CD34+/-CD40+1-sIg-) consistent with B-cell precursor ALL. Immunophenotyping. The surface antigen profiles of freshly isolated B-cell precursor ALL blasts were analyzed by indirect immunofluorescence and flow cytometry using a panel of monoclonal antibodies (mAb) that define human leukocyte differentiation antigens as previously described (17) (18) (19) (20) (22) (23) (24) (25) . After irradiation, 1 X 105 ALL blasts per sample were assayed in duplicate for LPC-derived B-cell precursor ALL blast colony formation, as described in the next paragraph. The surviving fractions ofclonogenic blasts were determined using the formula: Percent survival = 100 X (mean number of colonies in irradiated samples)/(mean number of colonies in unirradiated control samples). The radiation survival curves were constructed using computer programs for the analysis of cell survival data according to the single-hit multitarget and linear quadratic models, as detailed under Data analysis hereinafter. Data were expressed as the mean±SE values for SF2 as well as the a (initial slope reflecting the steepness of the linear component of cell killing) value of the linear quadratic model.
Colony assays for primary clonogenic blasts from B-cell precursor ALL patients. A small fraction ofleukemic B-cell precursors from ALL patients proliferate in response to low molecular weight B-cell growth factor (L-BCGF; Cellular Products, Buffalo, NY) and form compact blast colonies (20, 25, 26, 27 ). Day 7 ALL blast colonies are very compact and have a small size containing lymphoblasts (20, 27) . Therefore, colony numbers up to 3,000 per Petri dish can easily be enumerated on a grid using an inverted phase microscope of high optical resolution (20, 27) . In the present study, fresh ALL marrow blasts (1 X I0 5 blasts/ ml, duplicate I -ml samples) were irradiated and immediately plated in 35-mm Petri dishes for a 7-d culture at 370C in a humidified 5% CO2 atmosphere in alpha-MEM. Medium was supplemented with 0.9% methylcellulose, 50 uM 2-mercaptoethanol, 15% human plasma + 15% fetal bovine serum (or 30% calf bovine serum), and 10% (vol/vol) L-BCGF (20, (25) (26) (27) ). On day 7, blast colonies containing > 20 cells were counted using an inverted phase microscope with high optical resolution. After the enumeration of colonies in each petri dish, colony blasts were subjected to morphological and immunological analyses, as described (20, (25) (26) (27) (28) (29) (30) . In all experiments, culture dishes were examined immediately and 24 h after plating to exclude the possibility of clumping unrelated to proliferation, which might lead to wrong conclusions regarding the radiation sensitivity of clonogenic blasts.
Data analysis. The radiation survival curves were constructed using three computer programs for the MacIntosh, ENTER, DSUM, and FIT (kindly provided by Dr. N. Albright, Department of Radiation Oncology, University of California, San Francisco, CA), for the analysis ofcell survival data according to the singe-hit multitarget and linear quadratic models of cell survival ( 14, 22) . The data in this study were expressed as SF2 value representing the radiation sensitivity parameter ofthe singe-hit multitarget model of cell survival, as well as the a value representing the radiation sensitivity parameter of the linear quadratic model of cell survival ( 14, 22) . We used standard statistical methods, including Student's t tests, to evaluate the in vitro radiation survival data and to compare the radiobiologic features of primary clonogenic blasts from different patients, as previously described (22, 25) . Chi square analyses were used to assess the degree of association between clinical/laboratory parameters and radiation resistance/sensitivity of LPC. All computations were performed using an updated statistics program for the MacIntosh (StatWorks; Cricket Software, Philadelphia, PA).
Results
Radiobiologicfeatures ofprimary clonogenic blastsfrom newly diagnosed B-lineage ALL patients. Primary bone marrow blasts from 44 patients were exposed to ionizing radiation, cultured in the presence of L-BCGF, and assayed for LPC-derived . 85% had SF2 values 2 0.5 (Fig. 2) . Similarly, 90% of cases with Go,, 2 85% versus 37.5% of cases with Go,, < 85% had a values < 0.2, consistent with radiation resistance according to linear quadratic model of cell survival (Fig. 2) . Furthermore, univariate analysis using Go,I and S phase percentages as continuous covariates established a significant association between Go,1, as well as S phase percentages and SF2 (%Go0I versus SF2: . Similarly, when patients were divided into groups, patient sex, age, WBC at diagnosis, or in vitro plating efficiency did not have a significant impact on the radiation sensitivity of LPC (Table I ).
In our initial analyses ofimmunophenotype-radiation sensitivity associations, we used antigen expression on 2 30% blasts as an arbitrary criterion for positivity. According to this conventional classification, 17 of31 patients (55%) were CDl9+CD34+, and 14 of 31 patients (45%) were CD19'CD34-. When CDl9'-CD34' versus CD19'CD34-patients were compared, a trend towards higher SF2 and lower a values was observed in LPC from CD34+ patients, consistent with greater radiation resistance (Table I) . By comparison, a trend towards lower SF2 and higher a values was observed for CDl 9+CDI0+ patients and CD40 expression was not associated with radiation resistance or sensitivity of LPC from CDl9+ B-lineage ALL patients (Table I ). There were not enough CD 19-or CD24-patients to examine the potential influence of lack or presence of CDl9 or CD24 on LPC radiation sensitivity. To further investigate the influence of CD34 expression on radiation sensitivity at the level of LPC, patients were divided into three approximately equal groups based on increasing levels of CD34 expression (Table I) . A clear ordering effect was observed, indicating that increased CD34 expression levels are associated with significantly higher radiation resistance at the level of B-lineage LPC. The highest CD34 expression group (2 75% positivity) had 1.4-fold higher SF2 (P = 0.05) and twofold lower a values (P = 0.05) than the lowest CD34 expression group (< 30% positivity). As shown in Fig. 3 21 of 27 (78%) radiation sensitive cases were < 10 yr of age. The mean age was 4.5±0.8 yr for the radiation resistant group and 6.2±0.9 yr for the radiation-sensitive group (P = 0.2). A trend towards lower WBC values was noted among radiation-resistant cases (Table   II) . Whereas only 25% of radiation resistant cases had WBC > 100,000, some 50% of radiation-sensitive cases had WBC > 100,000. The mean WBC values were 91±39 X 109/liter for radiation-resistant cases and 170±46 X 109/liter for radiationsensitive cases (P = 0.2). The sex distribution of patients with radiation-resistant versus radiation-sensitive LPC were not significantly different (Table II) . Notably, a greater fraction of radiation-resistant cases had high Go, 1 phase percentages (2 85%) (80% versus 25%, P = 0.02) and low S phase percentages (< 13%) (70% versus 25%, P = 0.06) than radiation sensitive cases (Table II) , in accordance with the association between high GO/, phase percentage or low S phase percentage and radiation resistance shown in Table I Radiation resistance was defined as SF2 2 0.50 and a < 0.2. Continuous covariates were compared using two-sample, two-sided Student's t tests. Chi-square analyses were used to assess the degree of association between clinical/laboratory parameters and radiation resistance/sensitivity of LPC. P values are given only for significant or nearly significant (P < 0.1) differences/associations.
radiation-sensitive cases but only 18% of radiation-resistant sensitive groups were noted relative to expression of CD10, cases had a high proliferative index (%S + G2M . 16%) (P CDl 9, CD24, or CD40 antigens. = 0.02) (Table II) . Importantly, a greater fraction ofradiationresistant cases were CD34 + (73% versus 38%, P = 0.04) and the Discussion mean CD34 positivity of radiation-resistant B-cell precursor ALL cases was greater than the mean CD34 positivity of radia-Until recently, very little was known regarding the radiobiotion-sensitive cases (56±9% versus 34±9%, P = 0.09) ( ( 16, 42) . In conjunction with a values < 0.2 Gy-', our results are consistent with marked intrinsic radiation resistance at the level ofclonogenic blasts using the multitarget and linear quadratic models of cell survival. Thus, primary clonogenic blasts from some B-cell precursor ALL patients are clearly among the most radiation resistant human tumor cells reported to date. Early and frequent relapses experienced by Bcell precursor ALL patients within the first 6 mo after 800 cGy single dose or 1,375 cGy hyperfractionated TBI and BMT with only 10-15% disease-free survival at 2 yr after BMT are in accordance with this conclusion (2, 6, 11, 13) . Taken together, these preclinical and clinical observations in B-cell precursor ALL emphasize the need for therapeutic innovation and recommend a reevaluation of the role of TBI in BMT.
The observed radiobiologic heterogeneity among B-cell precursor ALL patients encouraged us to assess the radiobiologic features of primary B-lineage LPC in relation to the more frequently measured diagnostic parameters ofage, sex, WBC at diagnosis, cell cycle distribution, proliferation index of leukemic blasts, and immunophenotype. Among these diagnostic parameters, only cell cycle distribution and immunophenotype showed a significant correlation with the intrinsic radiation sensitivity of B-lineage LPC. A trend towards lower SF2 and higher a values was observed for CDl 9+CDI0+ patients, consistent with greater radiation sensitivity. By comparison, an opposite relationship existed between CD34 expression and radiation sensitivity of LPC. LPC from CD19+CD34+ patients appeared to be more radiation resistant than LPC from CD 19 + CD34 -patients, as reflected by higher SF2 and lower a values. When patients were divided into three approximately equal groups based on increasing levels of CD34 expression, a clear ordering effect was observed indicating that increased CD34 expression levels are associated with significantly higher radiation resistance at the level of B-lineage LPC. The highest CD34 expression group (2 75% positivity) had 1.4-fold higher SF2 (P = 0.05) and 2.0-fold lower a values (P = 0.05) than the lowest group (< 30% positivity). Importantly, a greater fraction of radiation resistant cases were CD34+ (73% versus 38%, P = 0.04) and the mean CD34 positivity of radiation resistant B-cell precursor ALL cases was greater than the mean CD34 positivity of radiation sensitive cases (56±9% versus 34±9%, P = 0.09). Taken together, these results prompt the hypothesis that high level CD34 expression is associated with radiation resistance in B-cell precursor ALL. CD34 expression has also been associated with resistance to chemotherapy in myeloid malignancies (52, 53) and may be related to poor treatment outcome in B-cell precursor ALL (based on unpublished observations in 1992 by F. M. Uckun, H. Sather, and D. Hammond of the Children's Cancer Study Group).
Human CD34 is a 1l0-kD lymphohematopoietic progenitor cell associated surface sialomucin antigen that is expressed on normal as well as leukemic progenitor cell populations corresponding to the earliest stages of differentiation (54) (55) (56) (57) (58) . The gene for CD34 has been mapped to band 1q32 ofthe long arm of chromosome 1 (59, 60) . CD34 cDNA predicts a 373-amino acid polypeptide that is a type I integral membrane protein and has no sequence homology to any known protein (58) . Notably, > 30% of the predicted amino acids in the NH2-terminal domain of this antigen are serine or threonine residues and CD34 antigen is a substrate for protein kinase C (PKC) (58, 61 (65) (66) (67) (68) (69) . Kimler and Anderson reported that 9L rat brain tumor cells are most resistant to radiation while in G1 phase (70) . Weichselbaum explained that the repair of radiation-induced molecular damage may be facilitated if DNA replication is delayed by holding cells in G1 (71 ) . Potmesil and Goldfeder reported that nonproliferating G. confined cells from mouse mammary adenocarcinoma cell lines DBAH and MT2 persist in irradiated tumors of mice and a transition of these nonproliferating cells to the proliferating pool takes place at the start of tumor recurrence (67) . In contrast, Wallen et al. reported that quiescent cells from the murine mammary carcinoma cell lines 66 and 67 are significantly more sensitive than proliferating cells from the same cell lines (72) . Similarly, Madoc-Jones reported that rat sarcoma cells are most sensitive to ionizing radiation during the GI phase of the cell cycle (73).
These reports regarding the radiation sensitivity of quiescent G1 cells indicate that the most sensitive and resistant phases of the cell cycle may be different for each cell type. Alternatively, not only the exact time of radiation exposure in relation to cell cycle, but also the length of a given cell cycle phase during which the radiation exposure occurred may determine the biological outcome of radiation exposure. In the present study, a high Go,, percentage or low S phase percentage in leukemic blast populations from newly diagnosed B-cell precursor ALL patients was associated with radiation resistance at the level of LPC. The observed relationship between cell cycle kinetic features and radiation sensitivity recommends agents that can stimulate S phase entry of quiescent ALL blast populations, such as mitogenic cytokines as potentially useful adjuncts to current TBI/BMT regimens for high risk B-cell precursor ALL.
Notably, high WBC at diagnosis was not associated with radiation resistance at the level of LPC. Therefore, the published ability of this factor to predict relapse after TBI and BMT in B-cell precursor ALL (2-9) cannot be explained by the level of radiation resistance.
In summary, we have used in vitro colony assays to study and compare the radiobiologic features of B-lineage LPC from newly diagnosed B-cell precursor ALL patients. Our findings demonstrate a marked interpatient variation in the radiation sensitivity of LPC. We postulate that clonogenic blasts with an inherent and/or acquired resistance to radiation contribute to the high relapse rate after BMT for B-cell precursor ALL. Differences in radiation sensitivity may partially explain the inconsistent responses of B-cell precursor ALL patients to TBI and BMT. The insights acquired from this study should promote sequential comparative analyses of novel radiosensitizing agents, which may ultimately provide more effective conditioning regimens.
